The FDA-cleared implant is patient specific, unlike traditional off-the-shelf implants, allowing a personalized fit for each patient’s spine, according to a March 27 press release.
Addressing the unique anatomy of each patient allows for fewer complications, better outcomes and lower costs of care.
The technology was brought to Sarasota Memorial by orthopedic surgeon and spinal implant specialist Ashvin Patel, MD.
While Aprevo was originally cleared to treat the lumber area of the spine, the device was granted a second “breakthrough device designation” by the FDA to develop implants for patients with cervical spine disease.
Sarasota Memorial is now a part of the Compass personalized spine surgery study, which will track Aprevo outcomes for two years for eligible patients who wish to enroll in the study.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
